Our co-chair, John Puntis, responds to the news that Palantir will be allowed to continue
Health minister James Frith told MPs on Monday 16th November that the current contract with Palantir for the NHS Federated Data Platform (FDP) would continue until March 2029 as the government aimed to procure a new version. The new procurement would focus on interoperability, resilience, and trusted common standards in a “new FDP iteration” which would “welcome international and UK capability alike – whether that is UK small and medium-sized enterprises that want a crack at NHS contracts, sovereign AI-backed capability in the UK or any international provider worth merit.”
Note that this does not preclude Palantir from tendering.
Two more years of Palantir is a setback. The possibility of ending Palantir’s involvement in the NHS two years from now is welcome but not guaranteed and falls short of what is needed. We would not have reached this point but for tireless campaigning across many organisations, NHS staff bravely speaking out about the deficiencies of Palantir’s software, opposition both from some MPs and two select committees and, finally, the government waking up to the reality of diminishing public trust.
It could have been different
The FDP contract was due to lapse in March 2027 unless renewed by Ministers before the end of December 2026 (a trigger point confusingly and incorrectly referred to as ‘the February break clause’). James Frith has now confirmed the contract extension.
But this decision is wrong. There are clearly many UK firms who could step in to replace Palantir. The current contract requires that Palantir submits an exit plan and provides any reasonable assistance that is requested to ensure continuity and facilitate an orderly transfer of responsibility. Government has not explained why it is now essential for the contract to be extended for two years when this decision means that this US spy tech firm will continue to receive millions of pounds of public money and further lock in dependence on its software.
On this point, the Whole-Life Programme Cost of the contract has been revised upwards to £1.1 billion by the National Infrastructure and Service Transformation Authority, while forecast benefits have fallen to £808 million. Frith confirmed that the contract did indeed include exit and transition provisions and that migration was “possible in principle” but maintained that launching a new FDP procurement was the “responsible thing” to do to maintain continuity of care for patients “who were benefitting from the existing arrangements.”
Palantir’s reaction to the decision is telling. Relying on highly paid ‘influencers’ such as Lord Tom Watson and former Met Police Commissioner Cressida Dick, Palantir’s chief lobbyist framed the government’s decision as a win for the company. According to Foxglove, an email from Palantir sent to MPs said the FDP contract extension was now a “certainty” and Palantir would be “setting out how Palantir UK would use that time to better position itself for future contracts.” Bear in mind that many questioned the fairness around how Palantir operates and how it won the original contract, with claims of an unfair head start, close political links, and extreme secrecy. In addition, the contract was said to be designed in a way that made it almost impossible for anyone but Palantir to win. The original tender even contained phrases that were taken from Palantir’s internal documents.
Negative reactions to the two-year extension
The British Medical Association representing doctors expressed disappointment at the extension, commenting that it will continue to call for a “complete and utter split” between the NHS and Palantir, and for it to be replaced with a “suitable and trustworthy alternative that aligns with the health service’s values”. The tech-justice and legal advocacy firm Foxglove Legal (which set up the ‘No Palantir in our NHS’ coalition) observed that “while we have now had warm words in parliament from ministers about a new procurement in 2029 to find a new supplier, at the moment, that’s all they are – words. So, the battle starts here to force ministers to stick by what they said in parliament yesterday, to kick Palantir out of the NHS once and for all.”
Doctors Association UK said the contract extension was a “missed opportunity” commenting that “Getting a commitment that the current contract will end in 2029…is not the same as getting Palantir out of the NHS. The Government has left the door open to the company bidding for the next contract. We need a clear commitment that this is the end of Palantir’s involvement in our NHS, not simply the end of one contract.” A joint statement from the ‘No Palantir in the NHS’ coalition asserted that “the government should have used the 2027 ‘break clause’ opportunity. Setting the end date at 2029 only hands Palantir more time in the NHS to lock us in.”
In addition, some MPs expressed their opposition in the course of parliamentary debate making highly relevant points that deserved (but did not always obtain) clear answers from government. Dame Chi Onwurah MP (chair of the Science, Innovation and Technology Select Committee) pointed out that “If a break clause cannot be exercised because of continuity of care, it is not a break clause; it is a lock-in.” She then asked whether assurances given to her committee about contractual continuity provisions had been mistaken and asked about adopting open-source technology, citing France and Germany.
Frith’s inadequate responses included the claim once again that one reason for extension was the benefit being delivered by the existing programme. Rachael Maskell MP challenged the evidence for Palantir’s effectiveness. She said some providers counted as ‘live’ had barely used the platform, while clinicians reported that its limitations impeded their work. Imran Hussain MP questioned the description of a two-year extension as a ‘transition’ to a replacement supplier. He queried the length of the process when a break clause already existed and raised both patient-data concerns and Palantir’s involvement in Israel’s military operations in Gaza. Frith returned to the decision having been based on benefits to patients. This claim is of course strongly contested if not indeed bogus.
Is Palantir’s FDP currently delivering benefits?
Many of those working in NHS IT have expressed scepticism about the benefits of the FDP, with some local NHS trusts and bodies refusing to comply with the roll-out. An investigation by Foxglove found that almost a third of English hospital trusts using the FDP tool were carrying out fewer operations than before they started using it. A pilot study at Chelsea and Westminster Foundation Trust of a precursor of the FDP developed by Palantir was promoted to persuade other hospitals to sign up. Problems were then highlighted in the British Medical Journal. While it was claimed that the inpatient elective surgery waiting list had been brought down by 28%, in fact, improvements were most likely due to post-pandemic recovery with other data showing no meaningful difference between FDP adopters and non-adopters. There was no evidence of a unique impact of the FDP at Chelsea and Westminster.
Up until May 2026, NHS England’s website was trumpeting how the FDP was delivering more procedures, shorter stays in hospital, improvements in cancer diagnosis, and reductions in referral time. Since then, it has added a note explaining that its claims of improvements are based only on before and after comparisons following the introduction of the FDP, and as such simply cannot generate firm conclusions about cause and effect given that other variables were not controlled for. In other words, while it remains a possibility, there can be no certainty about Palantir having delivered improvements in NHS performance. This resulted in the UK Statistics Authority investigating the Department of Health and NHS England over misuse of statistics and offering highly critical comments.
While a commitment to retendering the FDP contract is indeed a demonstration that campaigning works, it is premature to claim any sort of victory or to suggest that this spells the end of Palantir in our health service. In fact, our campaigning must now intensify, with calls on the government to reconsider its decision and take particular note of the views of patients and health workers together with those being expressed by trade unions. It is to be hoped that more of those unions already strongly opposed to outsourcing of NHS services and private sector involvement in healthcare, will add to the chorus of opposition, making bold representations to government in the coming days calling for Palantir to be kicked out of our NHS.
For more of our response to Palantir, see this video on our YouTube channel.

Good article. Despite the quote from Foxglove, the Government did not promise on 16 Nov to “kick Palantir out of the NHS once and for all” and your article makes that clear. James Frith’s full speech on 16 Nov is online at https://tinyurl.com/frith1
You write that ‘There are clearly many UK firms who could step in to replace Palantir’. KONP has always campaigned against private ownership within the NHS. So why, in this important case, does it appear to accept that a private British company would be preferable to a private American one? Through this whole campaign against Palantir, KONP should be calling for a publicly owned, in-house body to take care of NHS data.
Check out our video which makes this very clear: https://www.youtube.com/watch?v=5YjlnJPHnSU
Thank you for your forensic summary and analysis of this Government’s justification in burdening the NHS, patients, Drs and the taxpayer with 2 more unnecessary years of Palantir’s underwhelming software performance.
Also for pointing out the false claims made about their benefit to patients.
As a patient, I want them out of the NHS, I don’t want them to have access to my personal data – I don’t trust Palantir and now I have no faith in this Government.